559 related articles for article (PubMed ID: 33655500)
21. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
22. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
23. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
24. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
25. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.
Chai C; Cox B; Yaish D; Gross D; Rosenberg N; Amblard F; Shemuelian Z; Gefen M; Korach A; Tirosh O; Lanton T; Link H; Tam J; Permyakova A; Ozhan G; Citrin J; Liao H; Tannous M; Hahn M; Axelrod J; Arretxe E; Alonso C; Martinez-Arranz I; Betés PO; Safadi R; Salhab A; Amer J; Tber Z; Mengshetti S; Giladi H; Schinazi RF; Galun E
Gastroenterology; 2020 Sep; 159(3):999-1014.e9. PubMed ID: 32450149
[TBL] [Abstract][Full Text] [Related]
26. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
[TBL] [Abstract][Full Text] [Related]
27. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
[TBL] [Abstract][Full Text] [Related]
28. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease.
Toita R; Kang JH
Toxicol Lett; 2020 Oct; 332():1-6. PubMed ID: 32579995
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice.
Luo F; Ishigami M; Achiwa K; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Ishikawa T; Katano Y; Goto H
Dig Dis Sci; 2015 Sep; 60(9):2730-9. PubMed ID: 25868633
[TBL] [Abstract][Full Text] [Related]
30. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
Caddeo A; Kowalik MA; Serra M; Runfola M; Bacci A; Rapposelli S; Columbano A; Perra A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884910
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Hu L; Gu Y; Liang J; Ning M; Yang J; Zhang Y; Qu H; Yang Y; Leng Y; Zhou B
J Med Chem; 2023 Mar; 66(5):3284-3300. PubMed ID: 36799411
[TBL] [Abstract][Full Text] [Related]
32. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
Zhou J; Tripathi M; Ho JP; Widjaja AA; Shekeran SG; Camat MD; James A; Wu Y; Ching J; Kovalik JP; Lim KH; Cook SA; Bay BH; Singh BK; Yen PM
Thyroid; 2022 Jun; 32(6):725-738. PubMed ID: 35317606
[No Abstract] [Full Text] [Related]
33. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes.
Schumacher-Petersen C; Christoffersen BØ; Kirk RK; Ludvigsen TP; Zois NE; Pedersen HD; Vyberg M; Olsen LH
J Transl Med; 2019 Apr; 17(1):110. PubMed ID: 30943987
[TBL] [Abstract][Full Text] [Related]
34. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
35. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.
Gwag T; Ma E; Zhou C; Wang S
Liver Int; 2022 Apr; 42(4):829-841. PubMed ID: 35129307
[TBL] [Abstract][Full Text] [Related]
37. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
38. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
39. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
[TBL] [Abstract][Full Text] [Related]
40. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
